Join our email list!

Get daily updates delivered to your inbox
Thank you for subscribing

New Drug Reducing Progression of Primary Progressive MS


In this video from the Vall d’Hebron Barcelona Hospital Campus, Dr. Xavier Montalbán talks about the Phase 3 international study of a new drug developed by Roche called ocrelizumab.  The clinical trials have shown that patients with primary progressive multiple sclerosis (PPMS) see a reduction of clinical progression in at least 12 weeks.

The U.S. Food and Drug Administration is giving priority review to a request to approve ocrelizumab as a treatment for PPMS. Read more here.

The new drug gives much hope for those who live with this relatively rare form of multiple sclerosis.

Ocrelizumab is a humanized monoclonal antibody under clinical investigation and development by the Swiss pharmaceutical company Roche. Read more here.

Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?


  1. Kathleen Anderson says:

    I cannot afford the medicine as I am not on a drug plan; is there a way I can get it on a trial? I have PPMS, since 1994

  2. Jeanine Shahin says:

    It may be covered on the medical portion of your insurance since it will have to be administered in a hospital or infusion center setting.

Leave a Comment

Your email address will not be published. Required fields are marked *